TECHNOLOGY ACQUISITION AND FINANCING AGREEMENT

 

This Technology Acquisition and Financing Agreement (this “Agreement”) is entered into on May 12, 2020 (the “Effective Date”) for the collective acquisition, development, financing, implementation and commercialization of certain technologies that may be a potential treatment for the COVID-19 virus and its effects on the human body (collectively referred to herein as the “Joint Venture”) by and between:

 

Premier Biomedical, Inc. (OTC Pink: BIEI), a Nevada corporation (“Premier”),

 

Technology Health, Inc. (OTC Pink: HALB), a Colorado corporation f/k/a Halberd Corporation (“THI”),

 

RushNet Inc. (OTC Pink: RSHN), a Colorado corporation (“RushNet”), and

 

Gold River Productions, Inc., formerly XYZ Hemp, Inc. (OTC Pink: GRPS) a Colorado corporation (“Gold River”).

 

Each shall be referred to as a “Party” and collectively as the “Parties.”

 

RECITALS:

 

WHEREAS, Certain technologies owned by Marv Enterprises, LLC (“Marv”), a single member LLC owned and controlled by Dr. Mitch Felder (“Dr. Felder”), which have been exclusively licensed to Premier pursuant to a license agreement, as amended (the “Premier License Agreement”);

 

WHEREAS, Premier is publicly traded on the Pink Sheets, trading symbol BIEI;

 

WHEREAS, THI is publicly traded on the Pink Sheets, trading symbol HALB;

 

WHEREAS, RushNet is publicly traded on the Pink Sheets, trading symbol RSHN;

 

WHEREAS, Gold River is publicly traded on the Pink Sheets, trading symbol GRPS;

 

WHEREAS, RushNet, Gold River and Premier are parties to a Strategic Alliance Agreement dated July 19, 2019 (the “Patch Agreement”) concerning the development and marketing of Premier’s Anti-Addiction PatchTM Product;

 

WHEREAS, the Parties entered into a Strategic Alliance Agreement dated April 1, 2020 (the “April 1 Agreement”), concerning technologies owned by Marv concerning patented extracorporeal therapy (U.S. Patent 9,216,386 and U.S. Patent 8,758,287) (the “Marv Patents”);

 

WHEREAS, in addition to the safe removal of targeted antigens from the blood and targeted organs as contemplated by the April 1 Agreement, it is believed that the methodology described in the Marv Patents can remove both harmful, inflammatory cytokines and disease-causing targeted antigens from the bloodstream, as a multi-faceted COVID-19 Regiment Solution ETAT-Extracorporeal Targeted Antigens Technology, and therefore the April 1 Agreement is replaced in its entirety by this Agreement, and this Joint Venture will further include a separate intellectual property agreement that includes the licensure of Covid-19 Applications and Covid-19 Licensed Products (the “Intellectual Property Agreement”) to be entered into by and between Marv, as the owner, Premier, as the previous exclusive licensee, and THI as the current licensee. Applications in Appendix A which includes three provisional patents (the “Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus”, the “Method for Treating and Curing Covid-19 Infection”, and the “Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients”) (included hereafter in the definition of the Marv Patents in the Field of Coved-19 Treatments). A copy of the Intellectual Property Agreement is attached hereto as Exhibit A;

 

WHEREAS, this Agreement contemplates the development of a methodology for the extracorporeal treatment of a patient’s body fluid, for example, blood, and /or CSF (cerebrospinal fluid), with the utilization of laser technology for the emissive energy eradication of the COVID-19 virion. The resulting treatment would include a multiplicity of stages implementing a combination of technological innovations for the removal of body fluid from a patient which contains COVID-19 virions, tagging those virions with a fluorescent or luminous antibody, eradicating the fluorescently tagged virion with a laser, and then returning the cleansed body fluid to the patient. The resulting treatment would further include the Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus;

 

WHEREAS, the technologies represented by the Marv Patents in the Field of Covid-19 Treatments shall, after their licensure by THI, be referred to herein collectively as the “Covid-19 Licensed Products”;

 

 

WHEREAS, Premier has contacts (i) within various Veterans Administration hospitals, for the possibility of product testing of the Covid-19 Licensed Products, and (ii) with the University of Texas, El Paso (UTEP), including with regard to, and treatment of, COVID-19;

 

WHEREAS, the Parties are desirous of collaborating for the creation and distribution of products designed for the treatment of COVID-19 and the like;

 

WHEREAS, THI has a strategic relationship with Mohammed Zulfiquar and Datatecnics, Inc., for the development of a nano laser to eradicate the targeted antigens and the virus, with regard to the Covid-19 Licensed Products;

 

WHEREAS, Premier had 483,472,591 shares of its common stock outstanding as of March 16, 2020, but as of this date has 945,879,258 shares outstanding confirmed with the transfer agent as of this date;

 

NOW, THEREFORE, for good and adequate consideration, the receipt of which is hereby acknowledged, the Parties covenant, promise and agree as follows:

 

AGREEMENT

 

 

2.           TERMS OF THE AGREEMENT.

 

(a) Payments – Each of THI, Gold River and RushNet, and their respective associates, shall be responsible, jointly and severally, to cause $2,000,000 to be paid for various costs associated with this Agreement (such $2,000,000 amount to be hereinafter referred to as the “Technology Acquisition Fee”), to be paid as follows:

 

1. $20,000, which has already been paid to attorneys of Marv as it directed.

 

2. $80,000, payable to THI by no later than May 21, 2020.

 

3. $750,000, payable to THI by no later than June 7, 2020.

 

4. $1,150,000, payable to THI by no later than July 20, 2020, $500,000 of which would be payable to a subsidiary of THI to be formed in the United Kingdom, for research and development to be performed in the United Kingdom, by and at the direction of Mohammed Zulfiquar and/or Datatechnics Inc., as invoiced by Mohammed Zulfiquar and/or Datatechnics Inc., for expenses and at an hourly rate to Mohammed Zulfiquar and his designees.

 

(b) With the payments set forth above, Premier, THI and Dr. Felder, by and through the University of Texas El Paso (UTEP) and possibly others, as a part of this Joint Venture Agreement, will engage in a joint technology interplay with regard to the Covid-19 Licensed Products, including:

 

1.           for the creation create the fluorescent antibodies to find and target COVID-19 in bodily fluids.

2.           With the payments set forth above, Dr. Felder, by and through Mohammed Zulfiquar and/or Datatechnics Inc., modifies existing laser technology for eradicating identified and targeted antigens less than 10 nanometers in size.

3.           With the payments set forth above, Dr. Felder, by and through Mohammed Zulfiquar and/or Datatechnics Inc., will endeavor to create a tracking computer program for eradicating thousands of virions per second in CSF and blood (which is accomplished prior to returning the cleansed blood to the body).

4.           Not less than $500,000 of the Technology Acquisition Fee shall be budgeted for steps two and three above.

 

(c) Within three (3) trading days of the execution of this Agreement, the Parties, or at least THI, shall begin to issue a series of joint press releases (the “Joint Press Releases”), the contents of which will be agreed upon by all issuing Parties, concerning the existence of this Agreement and the developments by the Joint Venture.

 

(d) William Hartman will be appointed as the President and CEO of THI and as a member and Chairman of its Board of Directors.

 

2.     Each of THI, Gold River and RushNet shall, jointly and severally, use their best efforts to secure financing, including through grants and government contracts (Alternative Funding), including without limitation, NHS Innovation and, for the Joint Venture, currently estimated to be in the amount of Twenty-Five Million Dollars ($25,000,000), Enterprise Investment Scheme (EIS) and the Seed Enterprise Investment Scheme (SEIS). Any Alternative Funding secured for the Joint Venture which is paid to THI shall be considered part of the Technology Acquisition Fee. However, any amount secured by Premier as part of an SBA loan will only be counted toward the $2,000,000 Technology Acquisition Fee amount and credited to THI, Gold River and/or RushNet to the extent of 7.5% of the SBA loan amount. In the event that an amount greater than the Technology Acquisition Fee amount is paid to THI as a result of or as a part of this paragraph or the preceding paragraph, the additional funding shall be paid to, and administered jointly by, THI, Gold River and RushNet. 

 

                            

(a)           THI acknowledges that it has issued an aggregate of 450 million warrants, exercisable for a period of ten (10) years, at $0.01 per share and with cashless exercise provisions, to Dr. Felder (150 million shares), William Hartman (150 million shares), John Borza (75 million shares), and Heidi Carl (75 million shares) as consideration for services rendered in connection herewith.

 

(b)           In addition to the amounts payable pursuant to the Intellectual Property Agreement and the Technology Acquisition Fee, THI shall pay a 5% gross royalty amount to Datatecnics Inc. or Mohammed Zulfiquar and THI shall pay annually, within 30 days of its fiscal year-end, to each of RushNet and Gold River, 5% of its net income, as reduced by the foregoing payments.

(c)           Premier Biomedical shall not increase the number of authorized shares for at least eight months from the date of this Agreement.

 

3.      Term and Termination. This Agreement may be terminated by Premier, on thirty (30) days advance notice of termination, in the event the payments set forth in Section 2(a) hereof are not received by Premier on or before their respective due date.

 

4. No Brokerage Fee. Each Party hereby represents and warrants that there has been no agreement which might cause any other person to become entitled to a finder’s fee, a broker’s fee or a commission as a result of the transactions contemplated hereunder.

 

6. Nonexclusive Engagement; Extent of Services. The Parties agree that the relationship contemplated by this Agreement is a nonexclusive engagement/venture and that each Party now renders and may continue to render consulting services and/or sell or provide products to other companies that may or may not conduct activities similar to those of each other Party.

 

7. Non-circumvention, Confidentiality, Nonuse of Proprietary Information and Contacts. Each Party agrees to hold in confidence confidential information acquired in the course of this relationship with the other Parties and their associates. Each Party agrees to refrain from, either during period of this Agreement or at any other time thereafter, disclosing, using or disseminating such confidential information, for its or another’s benefit, in any way acquired in the course of any association arising out of this Agreement. For purposes of this Agreement, confidential information shall include contacts and introductions to third parties and information relating thereto. Confidential information, knowledge or data of a Party and/or its affiliates shall not include any information which is or becomes generally available to the public other than as a result of a disclosure by such Party or its representatives.

 

Each Party agrees that any party introduced (the “Introduced Party”) by the other Party (the “Introducing Party”) to (the “Other Party”), will permanently remain the “Introducing Party’s contact, and the “Other Party” will honor same and not contact such “Introduced Party,” except pursuant to this Agreement, without the consent of the Introducing Party. Furthermore, each Party agrees that for a period of three years from the date of this Agreement, should any dealings occur between the “Introduced Party” and the “Other Party,” either directly, indirectly, or through any affiliate or entity in which the “Other Party” receives a financial benefit, the “Introducing Party” of this Agreement shall be compensated with an interest in the profits of such business dealings equal to 50% of the financial benefit received by the “Other Party.”

 

8. This Agreement and the rights of the Parties hereunder shall be governed by and construed in accordance with the laws of the State of Nevada including all matters of construction, validity, performance, and enforcement and without giving effect to the principles of conflict of laws. Venue for any action brought under this Agreement shall be in the appropriate court in Clark County, Nevada.

 

9. The Parties agree and stipulate that each and every term and condition contained in this Agreement is material, and that each and every term and condition may be reasonably accomplished within the time limitations, and in the manner set forth in this Agreement. The Parties agree and stipulate that time is of the essence with respect to compliance with each and every item set forth in this Agreement.

 

10. This Agreement may not be amended or modified except by written agreement subscribed by all of the Parties to be charged with such modification. This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective partners, employees, agents, servants, heirs, administrators, executors, successors, representatives and assigns.

 

11. This Agreement, along with the exhibits hereto, sets forth the entire agreement and understanding of the Parties hereto and supersedes any and all prior agreements, arrangements and understandings related to the subject matter hereof. No understanding, promise, inducement, statement of intention, representation, warranty, covenant or condition, written or oral, express or implied, whether by statute or otherwise, has been made by any Party hereto which is not embodied in this Agreement or the written statements, certificates, or other documents delivered pursuant hereto or in connection with the transactions contemplated hereby, and no Party hereto shall be bound by or liable for any alleged understanding, promise, inducement, statement, representation, warranty, covenant or condition not so set forth.

 

12. This Agreement may be executed in one or more counterparts, each of which when executed and delivered shall be an original, and all of which when executed shall constitute one and the same instrument.

 

[remainder of page intentionally left blank; signature page to follow]

 

 

IN WITNESS WHEREOF, the Parties hereto, agreeing to be bound hereby, execute this Agreement upon the date first set forth above.

 

 

Premier Biomedical, Inc.:

 

 

/s/ William Hartman                                Date__________

By: William Hartman, CEO

 

 

 

THI Corporation:

 

 

/s/ James Christopher LeDoux               Date___________

By: CEO

 

 

RushNet Inc.:

 

 

/s/ Richard E Goulding                          Date___________

By: Richard E Goulding MD, Chairman of the Board

 

 

 

Gold River Productions, Inc.:

 

 

/s/ Richard E Goulding                          Date___________

By: Richard E Goulding MD, Chairman of the Board       

 

Exhibit A

 

Intellectual Property Agreement

 

INTELLECTUAL PROPERTY AGREEMENT

 

This Intellectual Property Agreement (this “Agreement”) is entered into on May 12, 2020 (“Effective Date”), concerning the pursuits set forth herein for the collective development, implementation and commercialization of a potential treatment for the COVID-19 virus and its effects on the human body (collectively referred to herein as the “Joint Venture”) by and between:

 

Marv Enterprises, LLC, a Limited Liability Company organized under the laws of the Commonwealth of Pennsylvania (“Marv”),

 

Premier Biomedical, Inc. (OTC Pink: BIEI), a Nevada corporation (“Premier”),

 

Technology Health, Inc. (OTC Pink: HALB), a Colorado corporation f/k/a Halberd Corporation (“THI”),

 

Each shall be referred to as a “Party” and collectively as the “Parties.”

 

RECITALS:

 

            WHEREAS, Marv is a single member LLC with Dr. Mitchell Felder as the sole member.

 

WHEREAS, Premier is publicly traded on the Pink Sheets, trading symbol BIEI.

 

WHEREAS, THI is publicly traded on the Pink Sheets, trading symbol HALB.

 

WHEREAS, Marv is owner of U.S. Patent 9,216,386 and U.S. Patent 8,758,287 collectively referred to as the “Issued Patents”.

 

WHEREAS, Premier has an Exclusive License to the Issued Patents via an Agreement executed by Marv and Premier on May 12, 2010 (“2010 Agreement”).

 

WHEREAS, Marv has subsequently filed numerous patent applications on subject matter related to the Issued Patents which are listed in Appendix A.

 

WHEREAS, Marv and Premier expanded Premier’s Exclusive License to include all the Applications listed in Appendix A via a Third Addendum to the 2010 Agreement executed by Marv and Premier on the Effective Date (“2020 Agreement”).

 

WHEREAS, Marv has filed US provisional patent applications specifically related to methods of treatment for Covid-19 as starred in Appendix A (Covid-19 Applications) to which Premier has an exclusive license via the 2020 Agreement.

 

WHEREAS, this Agreement contemplates the development of a methodology for the extracorporeal treatment of a patient’s body fluid to treat Covid-19 (Field of Covid-19 Treatment).

 

WHEREAS, the Parties are desirous of collaborating for the creation and distribution of products designed in the Field of Covid-19 Treatment (Covid-19 Licensed Products)

 

WHEREAS, THI is desirous of exclusively licensing the Applications listed in Appendix A;

 

WHEREAS, Premier is willing to assign its rights in the 2010 Agreement/2020 Agreement;

 

WHEREAS, Marv in this Agreement gives its written consent for Premier to assign its rights in the 2010 Agreement/2020 Agreement to THI; 

 

            NOW, THEREFORE, for good and adequate consideration, the receipt of which is hereby acknowledged, the Parties covenant, promise and agree as follows:

 

 

AGREEMENT

 

1.         RECITALS. The Recitals are hereby incorporated herein by this reference, as if fully restated herein.

 

2.      LICENSING. To the extent that terms in the 2010 Agreement/2020 Agreement are not contradicted or revised here, the terms as stated in 2010 Agreement/2020 Agreement remain in full effect, are controlling, and apply to THI licensing of the Applications in Appendix A and the Licensed Products derived therefrom.

 

(a) License - THI is granted the following rights to the Applications in Appendix A and the Licensed Products derived therefrom:

 

Scope. The licenses granted herein are exclusive worldwide licenses to:

 

1.         make, have made, use, lease, sell and import Licensed Products for the legal purposes of researching, developing, manufacturing, assembling, distributing, and selling the Licensed Products;

 

2.         make, have made, use and import machines, tools, materials and other instrumentalities, insofar as such machines, tools, materials and other instrumentalities are involved in or incidental to the research, development, manufacture, testing or repair of Licensed Products which are or have been made, used, leased, owned, sold or imported by the Licensee; and

 

3.         convey to any customer of the Licensee, with respect to any Licensed Product which is sold or leased to such customer, rights to use and resell such Licensed Product as sold or leased by Licensee (whether or not as part of a larger combination); provided, however, that no rights may be conveyed to customers with respect to any Invention which is directed to (i) a combination of such Licensed Product (as sold or leased) with any other product, (ii) a method or process which is other than the inherent use of such Licensed Product itself (as sold or leased), or (iii) a method or process involving the use of a Licensed Product to manufacture (including associated testing) any other product.

 

4.         Licenses granted herein are solely for products in the form sold by the Licensee and are not to be construed either (i) as consent by the Marv to any act which may be performed by the Licensee, except to the extent impacted by a patent licensed herein to the Licensee, or (ii) to include licenses to contributorily infringe or induce infringement under U.S. law or a foreign equivalent thereof.

 

5. The grant of each license hereunder includes the right to grant sublicenses to Related Companies for so long as it remains a Related Companies. Any such sublicense may be made effective retroactively, but not prior to the effective date hereof, nor prior to the sublicensee's becoming a Related Company.

 

           (b)      Reports and Payments – For the above exclusive licensing rights, THI will pay for various costs associated with this Agreement. The costs listed below are to be hereinafter referred to as the “License Fee”, to be paid by and through THI. The use of the License Fee is further broken down below:

 

1. $20,000, payable to Marv Enterprises, LLC or as it directs, which has already been paid into the account of Marv Enterprises, LLC at the Lynch Law Group

 

2. The total sum of non-paid invoices (estimated to be approximately $80,000) payable to Marv Enterprises, LLC, previously owed by Premier to Marv up until the effective date of this Agreement, payable in total by no later than July 20, 2020.

 

3. Reports.

      a . Within thirty (30) days after the end of each quarterly period ending on March

                31st, June 30th, September 30th, or December 31st, commencing with the one-year anniversary of the effective date of this Agreement, THI shall furnish to Marv a statement certified by a responsible official of the Licensee showing in a manner acceptable to Marv:

 

i. all Licensed Products which were sold, leased or put into use during such

quarterly period by THI or any of its Related Companies, the

gross sales received for the Licensed Products, and the Fair Market Values

of such Licensed Products;

 

ii. all services performed by THI or any of its Related Companies that

directly or indirectly used Licensed Product, the gross sales received by

the services, and the Fair Market Value of such services;

 

 

iii. the amount of royalty payable thereon, and

 

iv. if no Licensed Product has been so sold, leased or put into use or if no

services have been performed, the statement shall show that fact.

 

 b. Within such thirty (30) days, THI shall pay in United States dollars to Marv at PO Box 1332, Hermitage, PA 16148, or other address provided by Marv, the royalties payable in accordance with such statement. Any conversion to United States dollars shall be at the prevailing rate for bank cable transfers as quoted for the last day of such quarterly period by leading United States banks in New York City dealing in the foreign exchange market.

 

c. Overdue payments hereunder shall be subject to a late payment charge calculated at an annual rate of three percent (3%) over the prime rate or successive prime rates (as posted in New York City) during delinquency. If the amount of such charge exceeds the maximum permitted by law, such charge shall be reduced to such maximum.

 

(c) THI further agrees to pay Intellectual Property Prosecution and Costs Applications in Appendix A directly to Marv.

 

1. Costs. THI shall reimburse Marv for all IP Costs incurred on behalf of THI, as well as pre-paid IP Costs incurred prior to the Effective Date of this Agreement, including the costs of provisional and non-provisional applications that are filed to preserve Intellectual Property. Reimbursement for pre-paid IP Costs shall be in accordance with 2 (b) 2 above. 

 

2. Extension of Application. By written notice to Marv and at least ninety (90) days before the non-extendable due date for the filing of a national phase application of an Application, THI shall elect those countries or authorities in which it desires to file a patent application based on the Application. Intellectual Property rights in an unelected country shall revert to Marv.

 

3. Notice to Licensee. Before payment of any IP Cost, Marv shall notify THI for a time period being the lesser of (i) at least sixty (60) days before the IP Cost is due or (ii) as soon as is practicable after receiving knowledge of the IP Cost. The notice will identify (i) the Application or Patent, (ii) the country, (iii) the reason for the IP Cost, and (iv) the Due Date for payment. THI shall then affirm or deny payment. Affirmation of payment must be received by Marv within fourteen (14) days of the mailing date of the notice or the THI shall be deemed to have denied payment.

 

a. If THI affirms a payment, THI shall reimburse Marv for all IP Costs arising from the payment and shall then retain its license for the Application or Patent in that country.

 

b. If THI denies payment, THI shall have no obligation to pay IP Costs associated with the Application or Patent in that country, but the license and all associated rights for that Application or Patent shall revert to Marv.

 

4. Reimbursement by Licensee. THI shall prepay Marv for any affirmed IP Cost before payment is to be made by Marv. Marv shall have no duty to pay an IP Cost, whether affirmed or not affirmed, for which Marv does not receive prepayment. If THI does not pay Marv by the Due Date, the Application or Patent shall revert to Marv as if THI had denied payment under section 2(c)3.

 

 

5. Reversion of License. If a reversion occurs under this Article, the license in that country in which reversion has occurred will be terminated, and THI shall have no further right in the Application or Patent for that country. The right shall revert to Marv who will then have the right to pursue protection for the reverted Application or Patent. Marv has no further duty to THI for a reverted Application or Patent.

 

6. Applications. Defines as all applications of the United States and foreign countries, including Patent Cooperation Treaty applications that claim priority to the Applications listed in Appendix A, including any non-provisional applications, continuations, continuations-in-part, divisions, reissues, re-examinations or extensions thereof; and all applications including those applications filed in the United States or applications filed under the Patent Cooperation Treaty on subject matter directly related to the Applications in Appendix A whether or not priority to said applications was claimed.

  

(d)  Royalty Payments.

 

1. Royalty payments are payable from THI to Marv Enterprises, LLC and will be in the amount of 5% of the Fair Market Value of:

 

a. Licensed Product that is sold, leased or put into use by the THI or any Related Companies in the preceding calendar quarter; and

 

b. any service performed by THI or any Related Companies that directly or indirectly uses Licensed Product.

 

 

2. This License does not include a minimum annual royalty payable by THI to Marv.

 

3. Fair Market Value” means, with respect to any Licensed Product sold, leased or put into use, the Selling Price actually obtained in an arm’s length transaction for a product comprising a Licensed Product in the form in which the product is sold, whether or not assembled and without excluding any components or subassemblies thereof which are included in such Selling Price.

 

“Selling price” shall exclude: usual trade discounts actually allowed to unaffiliated persons or entities such as packing costs, costs of transportation and transportation insurance, and import, export, excise, sales and value added taxes, and custom duties.

 

4. In addition to the 5% amount calculated pursuant to the preceding paragraph, there shall be an identical 5% amount to be paid from THI, per Premier’s consideration, to certain shareholders of Premier, as identified by Premier, as of a record date to be determined in the future, on an annual basis, commencing on the one-year anniversary of this Agreement until a total amount of $40,000,000 has been paid to Premier. This royalty is separate and distinct from the royalty obligation to Marv as stated in 2(d)1.

 

         (e)     If THI does not make the obligatory payments as stated in 2(b) by the dates stated, the Exclusive License will revert back to Premier.

 

3.       JOINT VENTURE

 

(a)   Premier and THI will jointly cooperate in developing Covid-19 Licensed Products, to be memorialized by them in a Technology Acquisition and Financing Agreement. For the joint venture the following payments will be made by and through THI:

 

1. $750,000, payable to THI  in total by no later than June 20 , 2020. The payment will be for developing fluorescently-conjugated antibodies in the Field of Covid-19 Treatments.

 

2.    $1,150,000, payable to THI  in total by no later than July 30, 2020.     The payment will be for development of laser technology in the Field of Covid-19 Treatments.

 

3. $500,000 payable to a subsidiary of THI to be formed in the United Kingdom, for research and development to be performed in the United Kingdom, by and at the direction of Mohammed Zulfiquar and/or Datatechnics Inc. as invoiced by Mohammed Zulfiquar and/or Datatechnics Inc., for expenses and at an hourly rate to Mohammed Zulfiquar and his designees.

 

(b).     Premier may partner with other organizations as needed to effectuate the development of technology in the Field of Covid-19 Treatments.

 

(c) Marv will have no direct role in the development of technology in the Field of Covid-19 Treatment or in the Joint Venture. Marv, through its sole member Dr. Mitchell Felder, may from time to time be consulted regarding the development of technology in the Field of Covid-19 Treatment. This consultation will be done solely at Marv’s discretion.

 

(d)   Premier and THI may execute separate agreements further outlining the conditions of the Joint Venture to effectuate the development of technology in the Field of Covid-19 Treatment.

 

(e)     If THI does not make the obligatory payments as stated in 3(a) by the dates stated, the Exclusive License will revert back to Premier, provided, however, that in such event, THI would still be entitled to a proportionate interest in any Covid-19 Licensed Products, such portion being equal to a fraction, the numerator of which shall be the actual amount paid and the denominator of which shall be $2,000,000.

 

4.        NO BROKERAGE FEE. Each Party hereby represents and warrants that there has been no agreement which might cause any other person to become entitled to a finder’s fee, a broker’s fee or a commission as a result of the transactions contemplated hereunder.

 

5.  REQUIREMENT. The Parties agree that Marv and/or Mitchell S. Felder shall have no obligation and/or involvement in any capital raising activities for THI or Premier at any time and for any reason. Further, the 150,000,000 (one hundred and fifty million) stock warrants previously ceded to Mitchell S. Felder by Halberd/THI shall not be eliminated, cancelled, or altered in any way, and for any reason, unless specifically directed at the request of Mitchell S. Felder.

 

6.      NONEXCLUSIVE ENGAGEMENT; EXTENT OF SERVICES. The Parties agree that the relationship contemplated by this Agreement is a nonexclusive engagement/venture and that each Party now renders and may continue to render consulting services and/or sell or provide products to other companies that may or may not conduct activities similar to those of each other Party.

 

 

7.        CONFIDENTIALITY.

 

Each Party agrees to hold in confidence confidential information acquired in the course of this relationship with the other Parties and their associates. Each Party agrees to refrain from, either during period of this Agreement or at any other time thereafter, disclosing, using or disseminating such confidential information, for its or another’s benefit, in any way acquired in the course of any association arising out of this Agreement. For purposes of this Agreement, confidential information shall include contacts and introductions to third parties and information relating thereto. Confidential information, knowledge or data of a Party and/or its affiliates shall not include any information which is or becomes generally available to the public other than as a result of a disclosure by such Party or its representatives.

 

Confidential information should further include:

 

all information (in whatever form and whether or not marked or otherwise identified as confidential), including financial statements, business plans or records, concepts, marketing studies, projections, sales or pricing information, customer or supplier information, agreements with third parties, Intellectual Property (as defined below) or other data provided by or on behalf of the Disclosing Party to the Recipient and (ii) all notes, analyses, compilations, studies, interpretations or other material prepared by the Recipient or its Representatives which contain or reflect or are based upon, in whole or in part, information furnished by the Disclosing Party pursuant to this Agreement. “Confidential Information” does not include information which (a) is obtained by the Recipient from a third party who is not known to Recipient to be prohibited from transmitting such information to the Recipient, or (b) was already in the Recipient’s possession prior to its entry into this Agreement and which is not subject to any restrictions which would prohibit its disclosure to the Recipient in connection with the parties’ evaluation of the Transaction or (c) is or becomes generally available to the public other than as a result of a breach of any confidentiality restrictions to the Recipient.

 

“Intellectual Property” shall mean any Confidential Information proprietary to the Disclosing Party and any trademark, service mark, trade name, invention, improvement, discovery, patent, patent application, trade secret, copyright, copyrightable work, trade dress, mask work, computer program or any other type of proprietary intellectual property to which the Disclosing party claims any rights, including any registrations or applications for registration or renewals of any of the foregoing, and all copies and tangible embodiments of the foregoing in whatever form or medium. Confidential information shall also mean any information not generally made available or known to the public and shall include, without limitation, all ideas, inventions, software, documentation, flowcharts, diagrams, improvements, discoveries, research and development, know how, formulas, compositions, manufacturing and production processes and techniques, technical data, designs, drawings, plans, specifications, and all other information or material within the definition of a “trade secret” as set forth in the Uniform Trade Secret Act, or which either party otherwise reasonably considers proprietary.

 

Copies; Return of Confidential Information. The parties may copy or otherwise reproduce any written Confidential Information; provided, however, that all such Confidential Information and copies thereof shall be promptly returned to the Disclosing Party or, at the option of the Disclosing Party, destroyed, upon the Disclosing Party’s request, such destruction to be certified in writing.

 

8.           VENUE. This Agreement and the rights of the Parties hereunder shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania including all matters of construction, validity, performance, and enforcement and without giving effect to the principles of conflict of laws. Venue for any action brought under this Agreement shall be in the appropriate court in Mercer County, Pennsylvania.

 

 

9.       MATERIALITY. The Parties agree and stipulate that each and every term and condition contained in this Agreement is material, and that each and every term and condition may be reasonably accomplished within the time limitations, and in the manner set forth in this Agreement. The Parties agree and stipulate that time is of the essence with respect to compliance with each and every item set forth in this Agreement.

 

10.        AMENDMENTS/BINDING. This Agreement may not be amended or modified except by written agreement subscribed by all of the Parties to be charged with such modification. This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective partners, employees, agents, servants, heirs, administrators, executors, successors, representatives and assigns.

 

11.     ENTIRE AGREEMENT. This Agreement, along with the exhibits hereto, sets forth the entire agreement and understanding of the Parties hereto and supersedes any and all prior arrangements and understandings related to the subject matter hereof except for as specifically stated in this  Agreement with regards to the 2010 Agreement and the 2020 Agreement and  licensing rights. No understanding, promise, inducement, statement of intention, representation, warranty, covenant or condition, written or oral, express or implied, whether by statute or otherwise, has been made by any Party hereto which is not embodied in this Agreement or the written statements, certificates, or other documents delivered pursuant hereto or in connection with the transactions contemplated hereby, and no Party hereto shall be bound by or liable for any alleged understanding, promise, inducement, statement, representation, warranty, covenant or condition not so set forth.

 

12.       COUNTERPARTS. This Agreement may be executed in one or more counterparts, each of which when executed and delivered shall be an original, and all of which when executed shall constitute one and the same instrument.

 

13.     EXPENSES ASSOCIATED WITH THIS AGREEMENT. Marv shall be reimbursed in full for the cost(s) of all legal expenses associated with this agreement by THI. 

 

[remainder of page intentionally left blank; signature page to follow]

 

 

            IN WITNESS WHEREOF, the Parties hereto, agreeing to be bound hereby, execute this Agreement upon the date first set forth above.

 

 

Marv Enterprises, LLC:

 

 

/s/ Mitchell Felder                                  Date__________

By:  Mitchell Felder

 

 

THIRD ADDENDUM TO EXCLUSIVE LICENSE AGREEMENT

 

This THIRD ADDENDUM TO EXCLUSIVE LICENSE AGREEMENT (this “First Amendment”) is made as of the 11th day of May, 2020, by and between Marv Enterprises, LLC a Limited Liability Company organized and existing under the laws of the Commonwealth of Pennsylvania (“Marv”) with an address of P.O. Box 1332, Hermitage, PA 16148 and Premier Biomedical, Inc.., a Nevada corporation with its principal business address at 1362 Springfield Church Road, Jackson Center, PA 16133 (“Licensee”).

 

WHEREAS, Marv and Licensee have previously entered into an Exclusive License Agreement with effective date of May 12, 2010;

 

WHEREAS Marv and Licensee have previously entered into a First Addendum on August 17, 2011;

 

WHEREAS Marv and Licensee have previously entered into a Second Addendum on December 27, 2011; and

 

WHEREAS, the parties wish to further amend the Agreement as set forth herein to be consistent with the actions of the parties since the effective date of the Exclusive License Agreement up to an including the effective date of this Third Addendum.

 

NOW, THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt and sufficiency which are hereby acknowledged, the parties hereby agree as follows:

 

That under the Second Addendum 1.(i) and (ii), the Applications listed in Appendix A current as of the effective date of this agreement, are not refused by Premier and that Premier will pay Marv for expenses of all patent work. And that under 1. (iii), Premier will be the exclusive licensee under and as part of the Original Agreement.

 

IN WITNESS WHEREOF, the parties have executed this First Amendment as of the date first written above.

 

LICENSEE			LICENSOR
By        5/11/2020			By /s/ Mitchell S. Felder
William Hartman			Mitchell S. Felder
CEO and President of Premier Biomedical, Inc.			Marv Enterprises, LLC